Comparing two chemo doses for a type of AML with a specific genetic change
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a higher dose of cytarabine (a chemotherapy drug) is better than the standard dose for treating acute myeloid leukemia (AML) that has a specific gene change called RUNX1-RUNX1T1. It aims to find the most effective induction therapy for this subtype.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML, a type of blood cancer, with a specific gene change called RUNX1-RUNX1T1.
- You are between 14 and 60 years old.
- You have a good to fair performance status, meaning you can carry out daily activities with little or no help (ECOG score 0-2).
- Your liver and kidney function test results must be within certain limits, based on blood tests within the last 7 days.
- Your heart function, as shown by an echo test, must be above 50% ejection fraction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This trial tests a new combination of medications against a standard treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3-ITD mutation. The goal is to find out if the new combination works better and has fewer side effects. If you have this type of AML, you might be able to join and get access to newer drugs.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.